Skip to main content
Category

News Archive

emergent-biosolution-logo

Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to $25 Million to Supply Nerve Agent Antidote Auto-Injector NYSE:EBS

By News Archive

emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at up to approximately $25 million by the U.S. Department of State to supply TROBIGARD™ (Atropine Sulfate [2mg]/Obidoxime Chloride [220mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning. Trobigard is designed for intramuscular self- or buddy-administration of atropine sulfate and obidoxime chloride for pre-hospital intervention.  

Read More
funding-money-invest-pixa

The Geographic Concentration of Venture Capital – CityLab

By News Archive

funding-money-invest-pixa

When it comes to high-tech startups, we hear a lot about the so-called “rise of the rest.” As the nation’s leading centers of high-tech industry—places like the San Francisco Bay Area, New York City, Boston, and Seattle—have become increasingly expensive to live in, the argument goes, talented techies, entrepreneurs, and startups are moving to less expensive places like Portland, Pittsburgh, Detroit, Nashville, Las Vegas, and others.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.